Tag:
Biolex Therapeutics
Latest Headlines
Latest Headlines
Biolex reveals ePRO surprise; selection process
Biolex CEO Jan Turek notes something unforeseen in the ePRO element of the company's recent trial of a hepatitis C treatment: The degree of difference in reports of side-effect severity in the weekly
Biolex gives Unithink e-PRO a trial role
An electronic patient-reported outcome system has played a key role in a Phase II trial. The trial yielded positive results for a hepatitis C treatment from Biolex Therapeutics. During the trial,
Biolex gains $60M in VC cash, inks licensing deal
Just seven months after dropping its IPO plans in a brutal market environment, Biolex Therapeutics
Biolex garners $36M in second round
Biolex Therapeutics of Pittsboro, North Carolina, has rounded up $36 million in its second round of venture capital. Polaris Venture Partners led the round. Much of the money will go to develop its
